Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 12/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18888148 | 0.92 | MAP3K14 (0.67) | MAP3K14KDM4EL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL16516433 | 0.89 | MAP3K14 (0.63) | MAP3K14KDM4EALDH1A1SMN1; SMN2SCN9A | |
| SCHEMBL18673579 | 0.85 | MAP3K14 (0.49) | MAP3K14KDM4ESMN1; SMN2SCN9A | |
| SCHEMBL16517529 | 0.81 | MAP3K14 (0.65) | MAP3K14KDM4EALDH1A1TSHR | |
| SCHEMBL16517635 | 0.80 | MAP3K14 (1.00) | MAP3K14 | |
| SCHEMBL16517632 | 0.80 | MAP3K14 (1.00) | MAP3K14 | |
| SCHEMBL17921006 | 0.79 | MAP3K14 (0.74) | MAP3K14 | |
| SCHEMBL18888087 | 0.77 | MAP3K14 (0.75) | MAP3K14 | |
| SCHEMBL16517361 | 0.74 | MAP3K14 (0.47) | MAP3K14SMN1; SMN2SCN9A | |
| SCHEMBL16532335 | 0.73 | MAP3K14 (1.00) | MAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145034-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-9605005-B2 | Alkynyl alcohols and methods of use | GENENTECH, INC. (US) | 2017-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145034-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, RELA | MAP3K14 514/4885KDM4E 2080/4885L3MBTL1 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.